Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 16, 2023

BUY
$3.08 - $7.39 $20,944 - $50,252
6,800 Added 58.62%
18,400 $63,000
Q4 2022

Feb 14, 2023

BUY
$3.22 - $4.86 $37,352 - $56,376
11,600 New
11,600 $48,000
Q1 2022

May 16, 2022

BUY
$12.54 - $46.93 $367,422 - $1.38 Million
29,300 Added 623.4%
34,000 $552,000
Q4 2021

Feb 14, 2022

SELL
$45.28 - $74.5 $1.34 Million - $2.2 Million
-29,500 Reduced 86.26%
4,700 $223,000
Q3 2021

Nov 15, 2021

BUY
$57.18 - $84.43 $1.22 Million - $1.8 Million
21,300 Added 165.12%
34,200 $2.48 Million
Q2 2021

Aug 11, 2021

BUY
$47.86 - $83.95 $330,234 - $579,255
6,900 Added 115.0%
12,900 $1.08 Million
Q1 2021

May 17, 2021

BUY
$44.38 - $63.97 $266,280 - $383,820
6,000 New
6,000 $291,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $74.8M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.